Form 4: Tenaya Therapeutics Director Receives Stock Option Grant

Director Catherine Stehman-Breen was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Summary

• Director Catherine Stehman-Breen received a grant of 120,000 stock options on May 28, 2026.
• The options have an exercise price of $0.7989 per share.
• The grant is subject to a vesting schedule, with full vesting occurring on May 28, 2027, or the day before the next annual stockholders meeting, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company fundamentals.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Continued service as a provider to the issuer is required for the options to vest.

Future Outlook

The options are set to vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though investors should monitor total dilution levels.

Comparison to Industry Standards

• The use of the 2021 Equity Incentive Plan is consistent with standard corporate governance practices for mid-cap biotech firms.
• The one-year vesting cliff is a common retention mechanism for board members in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 28, 2027.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Form 4, Insider Trading, Stock Options, Equity Incentive Plan